725 recruiting. 725 Phase 2, 210 Phase 1, 38 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 725 | Recruiting 725 |
| Phase 1 | 210 | Recruiting 210 |
| Phase 3 | 38 | Recruiting 38 |
Follow Lymphatic Diseases: new trials by email Literature Review of Lymphatic Diseases trials Research Report on Lymphatic Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy of Early Second Infusion of Axi-cel Based on ctDNA for R/R Large B - Cell Lymphoma Infusion of Axicabtagene Ciloleucel - Relapsed/Refractory Diffuse Large B-cell Lymphoma | Phase 1 / Phase 2 | Recruiting | Zhujiang Hospital | 15 | 2027-02-01 | 2025-03-30 |
| Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene Biopsy Procedure, Biospecimen Collection, Computed Tomography - Burkitt Lymphoma, Double-Expressor Lymphoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 50 | 2027-01-11 | 2026-10-14 |
| Golcadomide in Combination With Rituximab for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy - Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma | Phase 1 / Phase 2 | Recruiting | City of Hope Medical Center | 58 | 2026-12-21 | 2026-10-22 |
| Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Acalabrutinib, Biospecimen Collection, Bone Marrow Biopsy - Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 2 | Recruiting | City of Hope Medical Center | 35 | 2026-12-19 | 2026-11-06 |
| Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Nemtabrutinib, Lisocabtagene Maraleucel - Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 20 | 2026-12-01 | 2026-10-29 |
| Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography - Richter Syndrome, Diffuse Large B-Cell Lymphoma | Phase 2 | Recruiting | Roswell Park Cancer Institute | 32 | 2026-11-15 | 2026-10-02 |
| Natalizumab for the Prevention of ICANS in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma Receiving CAR T-Cell Therapy Axicabtagene Ciloleucel, Biospecimen Collection, Brexucabtagene Autoleucel - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Mantle Cell Lymphoma | Phase 2 | Recruiting | University of Michigan Rogel Cancer Center | 26 | 2026-11-01 | 2026-10-23 |
| Nemtabrutinib and Venetoclax for the Treatment of Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | Recruiting | Jennifer Woyach | 25 | 2026-11-01 | 2026-10-15 |
| Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy - Conjunctival Mucosa-Associated Lymphoid Tissue Lymphoma, Gastric Mucosa-Associated Lymphoid Tissue Lymphoma | Phase 2 | Recruiting | City of Hope Medical Center | 35 | 2026-10-23 | 2026-10-29 |
| BEX101 in B-cell Non-Hodgkin's Lymphoma BEX101 injection - Non-Hodgkin's Lymphoma | Phase 1 / Phase 2 | Recruiting | Chinese PLA General Hospital | 20 | 2026-10-15 | 2026-10-22 |
| A Clinical Trial of MK-1045 in People With B-cell Cancer (MK-1045-006) MK-1045, Acetaminophen (or similar antipyretic), Diphenhydramine (or similar antihistamine) - Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma | Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 60 | 2026-10-14 | 2026-11-04 |
| Tafasitamab and Rituximab for the Treatment of Newly Diagnosed Follicular Lymphoma Rituximab, Tafasitamab, Biospecimen Collection - Classic Follicular Lymphoma, Grade 1 Follicular Lymphoma | Phase 2 | Recruiting | University of Washington | 30 | 2026-10-09 | 2026-10-15 |
| Study of JMBI-001 in Patients With MYC-Positive Advanced Cancers JMBI-001 Tablets - Advance Solid Tumors, Lymphoma, Non-Hodgkin | Phase 1 / Phase 2 | Recruiting | Chengdu Anticancer Bioscience, Ltd. | 150 | 2026-10-01 | 2026-10-15 |
| Venetoclax Plus Zanubrutinib for the Treatment of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | Recruiting | Kerry Rogers | 155 | 2026-10-01 | 2026-08-31 |
| ABBV-383 for the Treatment of Relapsed Refractory Waldenström Macroglobulinemia Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Waldenstrom Macroglobulinemia, Refractory Waldenstrom Macroglobulinemia | Phase 1 / Phase 2 | Recruiting | Mayo Clinic | 38 | 2026-09-30 | 2026-10-05 |
| Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies NX-5948, venetoclax, rituximab - B-cell Lymphoma, Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Recruiting | Nurix Therapeutics, Inc. | 150 | 2026-09-30 | 2026-11-03 |
| Intrathecal Cytarabine and Hydrocortisone for the Early Treatment of ICANS in Patients Undergoing CAR T Therapy for Non Hodgkin Lymphoma Therapeutic Hydrocortisone, Cytarabine, Dexamethasone - Non-hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma | Phase 2 | Recruiting | Vanderbilt-Ingram Cancer Center | 59 | 2026-09-25 | 2026-10-02 |
| Bendamustine Versus Fludarabine/Cyclophosphamide for Lymphodepletion in Chimeric Antigen Receptor T-cell Immunotherapy (CAR-T): a Randomized Trial. bendamustine hydrochloride, Cyclophosphamide, Fludarabine - B-cell Lymphoma | Phase 2 | Recruiting | Swiss Cancer Institute | 92 | 2026-09-24 | 2026-10-27 |
| GLORY: Glofit-GemOx With Liso-Cel For Lymphoma Obinutuzumab, Glofitamab, Gemcitabine & oxaliplatin - Lymphoma, B-cell Lymphomas | Phase 2 | Recruiting | Massachusetts General Hospital | 56 | 2026-09-15 | 2026-10-22 |
| A Phase 1/2 Study of UB-VV400 With Rapamycin in Relapsed/Refractory B-cell Malignancies UB-VV400, Rapamycin (sirolimus) - Lymphoma, B Cell, Lymphoma Non-Hodgkin | Phase 1 / Phase 2 | Recruiting | Umoja Biopharma | 274 | 2026-09-01 | 2026-10-09 |
Showing 20 of 725. Sign in to see all of them.
Lymphoma, Large B-Cell, Diffuse (119) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (112) · Lymphoma (106) · Lymphoma, Non-Hodgkin (95) · Leukemia, Lymphocytic, Chronic, B-Cell (77) · Lymphoma, Follicular (72) · Recurrence (71) · Lymphoma, Mantle-Cell (61) · Lymphoma, B-Cell (60) · Leukemia, Myeloid, Acute (51) · Burkitt Lymphoma (50) · Hodgkin Disease (40) · Lymphoma, B-Cell, Marginal Zone (39) · Leukemia (37) · Myelodysplastic Syndromes (33)
Hemic and Lymphatic Diseases (725) · Neoplasms by Histologic Type (678) · Immune System Diseases (673) · Immunoproliferative Disorders (671) · Neoplasms (665) · Lymphoproliferative Disorders (662) · Lymphoma (385) · Lymphoma, Non-Hodgkin (326) · Hematologic Diseases (288) · Leukemia, Lymphoid (228) · Leukemia (222) · Pathological Conditions, Signs and Symptoms (189) · Pathologic Processes (185) · Lymphoma, B-Cell (172)
Cyclophosphamide (101) · Rituximab (89) · Specimen Handling (60) · venetoclax (60) · Biopsy (49) · obinutuzumab (48) · fludarabine (47) · Dexamethasone (43) · Magnetic Resonance Spectroscopy (43) · zanubrutinib (40) · Prednisone (38) · Vincristine (37) · Lenalidomide (36) · Cytarabine (35) · Doxorubicin (32)
M.D. Anderson Cancer Center (39) · National Cancer Institute (NCI) (24) · Institute of Hematology & Blood Diseases Hospital, China (23) · City of Hope Medical Center (21) · Memorial Sloan Kettering Cancer Center (14) · AstraZeneca (11) · Chinese PLA General Hospital (11) · Fred Hutchinson Cancer Center (11) · Ruijin Hospital (11) · Sun Yat-sen University (11) · The First Affiliated Hospital of Soochow University (11) · Merck Sharp & Dohme LLC (10) · The First Affiliated Hospital with Nanjing Medical University (10) · The First Affiliated Hospital of Xiamen University (8) · Cancer Research UK (7)
United States (350) · China (249) · France (59) · Australia (57) · Italy (56) · United Kingdom (53) · Spain (51) · Germany (40) · South Korea (39) · Canada (36) · Israel (22) · Japan (22) · Denmark (21) · Belgium (19) · Sweden (19)
Matthew Krebs, Dr (5) · Weidong Han, Ph.D (5) · Bing Xu (4) · Mengyang Di, MD, PhD (4) · Zoe McQuilten, Professor (4) · Christopher J Melani, M.D. (3) · David McCall, MD (3) · Elias Jabbour, MD (3) · Liang Wang (3) · Michael Jain, MD, PhD (3) · Xiaofan Zhu, MD (3)
PMID 41671463, PMID 35622074, PMID 40550489, PMID 40802906, PMID 41698326, PMID 41843779, PMID 41894687, PMID 11282421, PMID 1244564, PMID 12778165, PMID 15049016, PMID 16195338, PMID 17410014, PMID 18596824, PMID 18623218, PMID 19141862, PMID 19597183, PMID 19731321, PMID 20660832, PMID 20930041, PMID 21270441, PMID 21502559, PMID 21576639, PMID 21719599, PMID 21821712, PMID 21847048, PMID 21847058, PMID 21953501, PMID 22442346, PMID 22851565, PMID 23255383, PMID 23589673, PMID 23674495, PMID 23716537, PMID 23818604, PMID 23860537, PMID 24652992, PMID 24876563, PMID 24974848, PMID 25113753, PMID 25275083, PMID 25396314, PMID 25402569, PMID 25403584, PMID 25799277, PMID 25966987, PMID 25999452, PMID 26194764, PMID 26291007, PMID 26308596
P30CA033572 (19), 2023 (16), 2025 (14), U10CA180886 (5), P30CA093373 (3), U10CA180888 (3), 2018 (2), P01CA078902 (2), P30CA015083 (2), P30CA015704 (2), U10CA180821 (2), UM1CA228823 (2), 2014 (1), 2017 (1), I01CX002685 (1)